GO
| HSI1 | 25,238.22 | -72.99 | 144.32B |
| HSCEI1 | 8,395.01 | -55.09 | 40.78B |
| Back Zoom + Zoom - Block Traded | |
|
2026-09-03 11:11:18 Citi published a research report stating that AI-driven drug discovery (AIDD) in China is accelerating, with AI's advantages in speed and cost efficiency attracting significant investor attention and interest. According to market research data, global pharmaceutical R&D investment is estimated at approximately USD313 billion in 2026, while AIDD penetration is only about 6%. Citi believes the growth potential is substantial and forecasts the global AI drug discovery ecosystem could reach approximately USD50 billion by 2030, mainly concentrated in three areas: data generation, wet lab validation and AI-native discovery. The broker believes INSILICO (03696.HK), as a hybrid company with both platform and pipeline capabilities, can continuously generate "higher-quality and differentiated" clinical assets through its proprietary AIDD platform, creating exponential value. Citi maintained its "Buy/High Risk" rating with a TP of HKD85, naming it the sector top pick. Citi initiated coverage on XTALPI (02228.HK) with a "Neutral/High Risk" rating and a TP of HKD8. The broker said its business integrates physical AI, robotic laboratories and intelligent orchestration, but noted that its product pipeline depth is limited and commercialization output remains to be validated. (gc/da)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |